nanoView Diagnostics Inc. (also dba NanoView Biosciences) is an early stage firm developing technologies for the detection and characterization of biofluid based nanoparticles, i.e. extracellular vesicles (EVs) and exosomes. EVs are being studied for diagnostic and therapeutic applications in high-impact areas like neurodegerative disease, cardiovascular disease, and cancer. Enabling simple detection of nanoparticles from complex samples like whole blood, serum, plasma, and urine, the VDXs developed technology simplifies the analysis and characterization of EVs as they are prepared for therapeutics or for use as an early biomarker of disease. Developing proprietary products that support research, translation and delivery of precision medicine, the Company' high-throughput, cost-effective analysis solutions enable life science researchers tbetter to understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
